Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984615 · ClinicalTrials.gov registry record
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
A clinical trial of BRAF Positive Metastatic Melanoma, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 1,961
- Enrollment target
- 1
- Study location
NCT05984615: Completed study of BRAF Positive Metastatic Melanoma, sponsored by Novartis Pharmaceuticals.
NCT05984615 is a study of BRAF Positive Metastatic Melanoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,961 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05984615, a study of BRAF Positive Metastatic Melanoma, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 1,961 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a retrospective real-world evidence cohort study.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,961 participants |
| Start Date | 2022-06-08 |
| Est. Completion | 2022-08-24 |
What the finished NCT05984615 record still lists
NCT05984615 is an observational study that tracks outcomes without assigning an intervention. Its 1,961 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with BRAF Positive Metastatic Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT05984615 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05984615 about?
NCT05984615 is a clinical study titled "Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients". This was a retrospective real-world evidence cohort study.
What is the current status of trial NCT05984615?
This trial is currently completed. The enrollment target is 1,961 participants. The study started on 2022-06-08. Estimated completion is 2022-08-24.
What conditions does trial NCT05984615 study?
This clinical trial studies the following conditions: BRAF Positive Metastatic Melanoma.
Who is sponsoring clinical trial NCT05984615?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05984615 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04251052 · 1,956 participants · NA
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- NCT06062394 · 1,980 participants · NA
Penn Medicine Healthy Heart
- NCT07321886 · 1,980 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- NCT05233150 · 1,932 participants · NA
Child-Adult Relationship Enhancement in Primary Care (PriCARE) / Criando Niños Con CARIÑO (CARIÑO)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI